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Abstract
Introduction: We examined the prognostic value of biologic subtype on locoregional recurrence (LRR) after
mastectomy in a cohort of low risk women who did not receive adjuvant radiation therapy.
Methods: A total of 819 patients with invasive breast cancer underwent mastectomy from January 2000 through
December 2005. No patient received preoperative chemotherapy. Estrogen receptor (ER) receptor, progesterone
receptor (PR) and human epidermal growth factor receptor 2 (HER2) status were used to construct the following 4
subtypes: i) ER+ or PR+ and HER2- (HR+/HER2-), ii) ER+ or PR+ and HER2+ (HR+/HER2+), iii) ER- and PR- and HER2+
(HR-/HER2+)and iv) ER- and PR- and HER2- (HR-/HER2-). LRR-free survival was estimated by the Kaplan-Meier
method. Cox proportional hazard models were used to evaluate the association between time-to-event outcomes
and patient prognostic factors.
Results: At a median follow-up of 58 months, five-year cumulative incidence of LRR for the entire cohort was 2.5%.
Subtype specific LRR rates were 1% for HR+/HER2-, 6.5% in HR+/HER2+, 2% for HR-/HER2+ and 10.9% for HR-/
HER2- (P < 0.01). In HER-2+ patients (irrespective of ER/PR status), trastuzumab therapy was not associated with
LRR-free survival. On multivariate analysis, one to three positive lymph nodes (HR 4.75 (confidence interval (CI) 1.75
to 12.88, P < 0.01), ≥ 4 positive lymph nodes (HR23.4 (CI 4.64 to 117.94, P < 0.01), HR+/HER2+ (HR 4.26 (CI 1.05 to
17.33), P = 0.04), and HR-/HER2- phenotype (HR 13.87 (CI 4.96 to 38.80), P < 0.01) were associated with shorter LRR-
free survival whereas age > 50 at diagnosis (HR 0.31 (CI 0.12 to 0.80), P = 0.02) was associated with improved LRR-
free survival. Among the HR-/HER2- subtypes, five-year LRR incidence was 23.4% in patients with positive lymph
nodes compared to 7.8% for lymph node negative patients (P = 0.01), although this association did not reach
significance when the analysis was limited to HR-/HER2- women with only one to three positive lymph nodes
(15.6% versus 7.8%, P = 0.11).
Conclusions: Constructed subtype is a prognostic factor for LRR after mastectomy among low risk women not
receiving adjuvant radiation therapy, although rates of LRR remain low across subtypes. Patients with node
positive, HR-/HER2- type tumors were more likely to experience LRR following mastectomy alone. Prospective
studies to further investigate the potential benefit of adjuvant radiation therapy in these women are
warranted.
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Introduction
The identification of biologic subtypes of breast cancer
has provided an important window into the underlying
heterogeneity of this cancer and has provided a new
paradigm for classification of this disease [1]. Since the
initial demonstration that these molecular subtypes cor-
related with differences in survival [2], other groups
have similarly confirmed the clinical relevance of the
biologic subtypes [3,4]. HER-2 amplified and basal sub-
types are associated with significantly worse overall sur-
vival while the luminal A subtype has a higher
expression of genes related to the estrogen receptor and
is associated with the best prognosis. Although the
initial description of molecular profiles of breast cancer
was based on transcriptional profiling, the practical chal-
lenges of this approach have led many to use clinical
approximations of these subtypes primarily using ER, PR
and HER2. Importantly, much of the clinical data on
patient related outcomes based on subtype utilizes this
clinical approximation, underscoring that they yield
results similar to those of studies utilizing the full gene
profile [5-7].
The impact of biologic subtypes on local regional
recurrence (LRR) outcomes has been less well studied.
Recent data in women with early stage breast cancer
undergoing breast conserving therapy suggests that
these biologic subtypes also confer a similar risk profile
for local recurrence as they do for distant disease [7-9].
Among women undergoing mastectomy, similar trends
appear to hold [9,10].
The role of chest wall and regional nodal irradiation
following mastectomy continues to evolve [11]. In many
cases, women undergoing mastectomy will not require
radiation therapy. However, based on clinical features,
some women felt to be at high risk for recurrence fol-
lowing mastectomy will be recommended for post-mas-
tectomy radiation therapy (PMRT). Biologic subtype of
breast cancer is not currently considered in the indica-
tions for PMRT, as increased risk for LRR based on sub-
type has not been as well established. The objectives of
this study were to determine the relevance of con-
structed biologic subtype (using ER, PR and HER2 as
surrogates) in predicting LRR following mastectomy in a
cohort of women deemed clinically low risk for locore-
gional recurrence who, thus, did not undergo PMRT.
Materials and methods
Patient selection
The study cohort included 819 women with invasive
breast cancer who underwent mastectomy at the Uni-
versity of Texas MD Anderson Cancer Center from Jan-
uary 2000 through December 2005. Seven patients who
presented with breast cancer were found to have a
contralateral cancer on imaging at presentation or on
prophylactic mastectomy pathology. In these patients,
the index breast cancer was used for analysis. Patients
with recurrent ipsilateral breast cancer after previous
breast conservation therapy were excluded. Two patients
with Stage IV disease were included in this analysis.
Neither received PMRT and both were found to be
Stage IV on postoperative staging work-up. Patients
receiving preoperative systemic therapy were excluded
from this analysis. No patient in this study received
adjuvant radiation therapy.
This study was approved by the MD Anderson Cancer
Center Institutional Review Board and waiver of consent
provided by the IRB; specific consent from the patients
to participate in the study and consent to publish the
resulting data was not required by the IRB.
Margin assessment
Margins were deemed positive only if there was tumor
on ink. Close margins were defined as tumor within 2
mm of ink. DCIS or invasive cancer > 2 mm from ink
was classified as a negative margin.
Treatment
Adjuvant systemic therapy was administered at the dis-
cretion of the treating oncologist. Although adjuvant
trastuzumab was not routinely used during the time of
this study, 28 out of 108 HER2 + patients in our cohort
were additionally treated with adjuvant trastuzumab.
Women with hormone receptor positive tumors (ER
and or PR > 10%) were advised to receive adjuvant hor-
monal therapy. Twelve patients with ER negative (<
10%) and PR negative (< 10%) cancers received hormo-
nal therapy, most for weakly hormone receptor positive
tumors (1% to 9% positive).
Follow up
Patients were generally seen in follow-up every three
months for the first two years and, subsequently, every
six months. Patients who did not routinely follow-up at
MD Anderson Cancer Center were contacted by phone
or mail for follow-up information. Follow-up time was
counted from date of diagnosis to the date of death,
date of first event or last confirmed date of breast can-
cer disease-free status. The median follow up time was
58 months (range 2.4 to 122 months).
Classification of biologic subtype
Four subtypes were constructed based on the receptor
status of the primary tumor: i) ER+ or PR+ and HER2-
(HR+/HER2-), ii) ER+ or PR+ and HER2+ (HR+/HER2
+), iii) ER- and PR- and HER2+ (HR-/HER2+)and iv)
ER- and PR- and HER2- (HR-/HER2-). ER and PR were
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considered positive if immunohistochemistry (IHC)
staining was 10% or greater [12]. An IHC score of 3+ or
HER2 amplification by fluorescence in situ hybridization
(FISH) score was used to determine HER2 positive sta-
tus. In the setting of 2+ IHC staining and no FISH data,
tumors were considered negative for HER2 [13]. Patients
with unknown biologic subtype constituted those where
HER2 testing was not performed. These patients were
included when characterizing the patient population as
a whole, but were excluded from subtype specific
analyses.
Statistical analysis
The primary end point of this study was time to local or
regional recurrence, defined as biopsy-proven recurrence
in the chest wall, skin, axilla, infraclavicular nodes, inter-
nal mammary nodes or supraclavicular nodes. The local
or regional recurrence free time was defined as the time
interval from the surgery date to the local or regional
recurrence date, death date or last follow-up date,
whichever occurred first.
Pearson’s Chi-Square tests were used to assess the
association of clinical variables among subtypes. The
Kaplan-Meier method [14] was used to estimate the
probability of overall survival as well as local or regional
recurrence-free survival. The long-rank test [15] was
used to compare the time-to-event outcomes among
subgroups of patients. The Cox proportional hazards
models [16] were used to assess the association between
the time-to-event outcomes and patient prognostic fac-
tors as well as constructed subtypes. Backward model
selection methods were used to determine the final
fitted models. P-values less than 0.05 were deemed sta-
tistically significant. All statistical analyses were con-
ducted in SAS 9.1 for Windows (SAS Institute Inc.,
Cary, NC).
Results
The characteristics of the 819 women in this analysis are
described in Table 1. The majority of patients presented
with early stage, node negative breast cancer. In this
mostly post-menopausal cohort, 80% had hormone sensi-
tive tumors as measured by ER or PR staining. Thirteen
percent of the women had HER2 overexpressing tumors;
of these, only one quarter received trastuzumab therapy.
There were significant differences across the con-
structed subtypes with regard to clinical, pathological
and treatment variables (Table 2), including median age
at presentation (P < 0.01), number of positive nodes (P
= 0.02) and grade (P < 0.01). Women with HR-/HER2+
tumors tended to be younger, while those with HR-/
HER2- tumors has the lowest incidence of nodal invol-
vement. Compared to all other cohorts, women with HR
+/HER2- had the lowest probability of grade 3 tumors.
As expected, the number of patients receiving hormonal
therapy and chemotherapy was also significantly differ-
ent (all P < 0.01) with the majority of women with ER
and/or PR positive tumors receiving endocrine therapy
and the majority of patients with HER2+ (irrespective of
ER/PR status) and HR-/HER2- tumors receiving
chemotherapy.
With a median follow-up of 58 months, the five-year
cumulative incidence of LRR was 2.5%. For patients
with HR+/HER2-, the five-year incidence of LRR was
1% (95%CI, 0.1% to 1.9%), compared with 6.5% (95%CI,
0 to 13.5%) in the HR+/HER2+ group, 2% (95% CI, 0 to
5.8%) for HR-/HER2+ and 10.9% (95% CI, 3.8 to 7.5%)
in the HR-/HER2- group (P < 0.01) (Table 2 and Figure
1). Although there were differences in overall survival
Table 1 Patient baseline characteristics (number = 819).
Characteristic Number %
Age at diagnosis
< 50 290 35.4





Number of positive nodes
0 586 71.6
1-3 219 26.7
> 4 10 1.2






ER or PR positive 656 80.1
HER2 positive 109 13.3
LVI present 137 16.7
Hormonal therapy received 553 67.5
Chemotherapy received 389 47.5













ER, estrogen receptor; HER2, human epidermal growth receptor 2; LVI,
lymphovascular space invasion; PR, progesterone receptor.
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Table 2 Patient characteristics by breast cancer subtype (Number = 819).
















Median age at diagnosis 55 56 54 49 54 <
0.01
T1 615 439 (76.48) 41 (71.93) 36 (70.59) 60 (63.83) 0.06
Positive lymph nodes 230 164 (28.57) 25 (43.86) 14 (27.45) 19 (20.21) 0.02
≥ 4 positive lymph nodes 10 7 (1.22) 0 0 3 (3.19) 0.25
Lymphovascular invasion 137 89 (15.51) 16 (28.07) 13 (25.49) 16 (17.02) 0.07
Modified Black’s nuclear grade 3 301 132 (23.00) 36 (63.16) 48 (94.12) 75 (79.79) <
0.01
Close or positive margins 27 17 (2.96) 0 3 (5.88%) 5 (5.32) 0.21
Hormonal therapy 556 473 (82.40) 50 (87.72) 5 (9.80) 6 (6.38) <
0.01
Chemotherapy 390 235 (40.94) 42 (73.68) 38 (74.51) 64 (68.09) <
0.01
Median follow-up (months) 58 58 55 62 53 0.11














Local recurrence incidence rate at 60 months
(95% CI)




0% 2.6% (0.7% to
10.5%)
0.06
Regional recurrence incidence rate at 60
months (95% CI)














































Figure 1 Log rank test of local regional recurrence free survival by tumor subtype.
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among the different subgroups, these did not reach sta-
tistical significance (P = 0.06) (Figure 2).
On univariate analysis, younger age at presentation
was associated with greater risk of LRR (HR 3.22 (95%
CI 1.28 to 8.33), P = 0.01) whereas ER- or PR-positive
tumors were associated with markedly lower risk of LRR
(HR 0.15 (95%CI 0.06 to 0.38), P < 0.01) (Table 3). Sig-
nificant predictors of locoregional failure also included
increasing tumor size, nodal involvement, increasing
pathologic stage, high grade and presence of lymphovas-
cular space invasion (LVI) (all P < 0.05). Among the
subtypes, HR-/HER2- had the highest risk of LRR
(HR13.6 (95% CI 4.63 to 39.7) P < 0.01). HER2 status,
when analyzed independent of HR status, was not signif-
icantly associated with LRR (HR 1.64, 95%CI 0.54 to
4.94, P = 0.38). However, within the constructed sub-
types women with HR+/HER2+ disease, but not those
with HR-/HER2+ disease, had significantly increased
risk of LRR when compared to HR+/HER2- tumors (HR
6.25 (95%CI 1.49 to 6.2), P = 0.01 and HR 2.24 (95%CI
0.26 to 19.2), P = 0.46, respectively). Administration of
trastuzumab to HER2+ patients did not significantly
alter LRR risk (HR 3.87 (95%CI 0.53 o 28.1), P = 0.18).
On multivariate analysis, ≥ 4 positive nodes and HR-/
HER2- subtype were the strongest predictors of LRR
failure (HR 23.4 (95%CI 4.64 to 117.94) and HR 13.87
(95%CI 4.96 to 38.8), respectively, P < 0.05) (Table 4).
Other variables that retained significant association with
LRR risk were one to three positive nodes (HR 4.75 (95%
CI 1.75 to 2.88), P = 0.02), age at diagnosis < 50 (HR 3.23
(95%CI 1.25 to 8.33), P = 0.02) and HR+/HER2+ subtype
(HR 4.26 (95%CI 1.05 to 7.33), P = 0.04).
We next explored whether women with HR-/HER2-
tumors could be further stratified for LRR risk by clini-
cal variables. The presence of lymphovascular space
invasion was also associated with increased risk of LRR
within the HR-/HER2- subtype (29.7% versus 9.23%, HR
= 3.44, P = 0.04) (Table 5). Similarly, patients with node
positive disease had increased probability of LRR at five
years compared to those who did not (23.4% versus
7.8%, HR = 4.44, P = 0.01) (Table 6). When women
with ≥ 4 nodes were removed from this analysis, LRR
among those women with one to three positive nodes
remained elevated but did not reach statistical signifi-
cance (15.6% versus 7.8%, P = 0.11).
Discussion
Classification of breast cancer by biologic subtype has
proven to be a strong predictor of distant relapse [2,3].


































ER-/HER2- (9/94) P=0.06 (log-rank test)
Figure 2 Log rank test of overall survival by tumor subtype.
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tumor biology as a determinant of local and regional
failure. In this report, we show that risk of chest wall
and regional nodal failure following mastectomy among
a cohort of women who did not receive adjuvant radia-
tion therapy is significantly different based on tumor
subtype. Specifically, while the overall risk of loco-regio-
nal failure is low in this cohort, it rises modestly in
women with HR+/HER2+ and significantly in women
with HR-/HER2- tumors. Even among women with
HR-/HER2- tumors, it is possible to further stratify
between those at modest risk and those at marked risk
of LRR by the presence of LVI and nodal involvement.
Table 3 Univariate Cox PH regression models for local/regional recurrence(LRR)-free survival (Number = 819).
Variable LRR-free
(Number = 800)
LRR (Number = 19) HR (95%CI) P-value
Age at diagnosis
> 50 522 7 reference
< 50 278 12 3.22 (1.28 to 8.33) 0.01
T stage
T1 604 9 reference
T2 187 8 2.95 (1.14-7.64) 0.03
T3 9 2 19.8 (4.24-92.3) < 0.01
Pathologic stage
I 450 4 Reference
IIA and IIB 335 11 3.74 (1.19-11.7) 0.02
IIIA, IIIB, IIIC and IV 15 4 31.8 (7.94- 127) < 0.01
Number of positive lymph nodes
0 579 7 reference
1-3 209 10 3.94 (1.50-10.3) 0.01
> 4 8 2 23.3 (4.83- 112) < 0.01
Modified Black’s nuclear grade
3 versus 1,2 6.93 (2.30-20.88) < 0.01
ER or PR
Negative 137 11 reference
Positive 648 8 0.15 (0.06-0.38) < 0.01
HER2+
Negative 653 15 reference
Positive 105 4 1.64 (0.54-4.94) 0.38
Lymphovascular invasion
Negative 555 9 reference
Positive 127 10 5.08 (2.06-12.5) < 0.01
Received trastuzumab (in HER2+ patients)
No 78 2 reference
Yes 26 2 3.87 (0.53-28.1) 0.18
Systemic therapy
No 141 3 reference
Yes 658 16 1.11 (0.32-3.80) 0.87
Constructed Subtype
HR+/HER2- 569 5 reference
HR+/HER2+ 54 3 6.25 (1.49-26.2) 0.01
HR-/HER2+ 50 1 2.24 (0.26-19.2) 0.46
HR-/HER2- 84 10 13.6 (4.63-39.7) < 0.01
CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth receptor 2; PR, progesterone receptor.
Table 4 Multivariable Cox PH regression models for local/
regional recurrence-free survival (Number = 819).
Variable HR (95%CI) P-value
1-3 positive lymph nodes 4.75 (1.75 to 12.88) < 0.01
≥ 4 positive lymph nodes 23.40 (4.64 to 117.94) < 0.01
Age < 50 at diagnosis 3.23(1.25 to 8.33) 0.02
HR+/HER2+ Subtype 4.26 (1.05 to 7.33) 0.04
HR-/HER2- Subtype 13.87 (4.96 to 38.80) < 0.01
CI, confidence interval; HER2, human epidermal growth receptor 2; HR,
hormone receptor.
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Although direct comparisons with other series is diffi-
cult given differences between cohorts, the pattern of
relatively higher risk among HR-/HER2- subtypes and
lower risk among HR+/HER2- subtypes seen in our
patient population is consistent with other series report-
ing on LRR following mastectomy. In a series of 1,000
high risk women, Kyndi et al. reported five-year rates of
LRR of 20% among women with HR-/HER2- tumors
who received PMRT compared to 3% in the subset of
patients with HR+/HER2- tumors receiving PMRT [10].
Using a six biomarker panel, Voduc et al. reported ten-
year LRR of 19% in tumors negative for ER, PR and
HER2 but expressing either CK5/6 or EGFR and 13%
among those tumors negative for all biomarkers [9]. In
contrast, ten-year LRR in women with HR+/HER2- and
low ki-67 tumors was 8%. This rate of locoregional fail-
ure appears high in this subgroup of women with estro-
gen responsive tumors, which is likely explained by a
sizeable number of women in this study who did not
receive adjuvant endocrine therapy despite expression of
hormone receptors. Thus, the actual rate of LRR follow-
ing mastectomy in women with HR+/HER2- tumors is
likely closer to that reported by our series and the series
by Kyndi et al.
We also did not find adjuvant trastuzumab to impact
LRR significantly. Results from both NSABP B-31 and
NCCTG N9831 trials demonstrate an approximately
50% reduction in combined local and regional events in
the arm randomized to receive adjuvant trastuzumab
[13]. Therefore, it is very likely that the lack of effect we
noted in our series is due to the small number of the
HER2+ patients who received trastuzumab.
An important difference between our studies and
those previously reported is the unexpectedly low rate
of LRR seen in our series among women with HR-/
HER2+ tumors (2%). This stands in distinction with the
higher rate of LRR seen among those with HER2+
tumors who also express hormone receptors (HR
+/HER2+) within our own series (6.5% versus 2%).
While only 25% of the total HER2+ cohort received
trastuzumab, there were no differences in the proportion
of women who received this treatment based on ER sta-
tus (28% in the HR+/HER2+ group versus 24% in the
HR-/HER2+ group). Thus, the differences we report in
LRR rates between the two HER2+ subsets may be due
to either small sample size or, potentially, differences in
responsiveness to trastuzumab-based therapy. Larger
datasets are required to further investigate this
possibility.
Lastly, our data demonstrate that while tumor sub-
types are associated with LRR outcomes, further stratifi-
cation by clinical variables classically associated with
increased risk remains valuable. Thus, women with
HR-/HER2- tumors, who have either positive nodes or
LVI, are at markedly increased risk of LRR. This is simi-
lar to the study by Abdulkarim et al. who reported that
LVI and nodal involvement were independently asso-
ciated with LRR in women with HR-/HER2- breast can-
cer [17]. These authors also noted that women with
early stage, node negative, HR-/HER2- breast cancer
treated with breast conserving therapy (BCT) had lower
five-year LRR risk compared to a similar cohort treated
with mastectomy without radiation. Rates of distant dis-
ease were not significantly different. Nonetheless, the
authors suggest that the benefit of adjuvant radiation
therapy needs to be investigated in all women with
HR-/HER2- breast cancer. However, our data show five-
year LRR risk for women who are node negative to be
well under 10%, the threshold generally used for admin-
istration of adjuvant radiation. Thus, the majority of
such women, if given radiation, would be expected to
derive no benefit. In contrast, for women with HR-/
HER2- tumors and one to three positive nodes, we
found a trend towards increase risk of LRR (5.6% versus
7.8%, P = 0.11). While the difference in our study did
not reach statistical significance, this is likely due to
small sample size and adjuvant radiation therapy in this
subset of HR-/HER2- breast cancers may be warranted
to improve both local-regional control and, based on
meta-analysis of randomized clinical trials by the Early
Breast Cancer Trialists’ Collaborative Group [18], survi-
val as well.
Table 5 Locoregional recurrence within HR-/HER2- subtype by presence of lymphovascular invasion (LVI) (Number =
80)
Variable Locoregional recurrence No recurrence LRR probability at 60 month P-value
LVI positive 4 12 29.7%
LVI negative 6 58 9.2% 0.04
Table 6 Locoregional recurrence within HR-/HER2- subtype by lymph node status (Number = 94).
Variable Locoregional recurrence No recurrence LRR probability at 60 month P-value
Node positive 5 14 23.4%
Node negative 5 70 7.8% 0.01
HER2, HER2, human epidermal growth receptor 2; HR, hormone receptor; LRR, locoregional recurrence.
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Conclusions
In summary, we found that constructed subtypes can
differentiate risk of LRR following mastectomy among a
cohort of women generally considered at low risk for
LRR. Overall, the risk of LRR in our study remains quite
low across subtype. The addition of clinical risk vari-
ables to HR-/HER2- subtype can identify a subset of
women at marked increase for LRR and for whom adju-
vant radiation may be considered.
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